The SERENA-6 trial showed improved survival by switching therapy upon ctDNA detection of ESR1 mutations. However, it required screening over 3,300 patients to randomize just 315, highlighting the immense scale, cost, and patient drop-off of applying this serial monitoring strategy in standard clinical practice.

The Lidara study showed SERD benefit in patients without pre-existing ESR1 mutations. Success is likely multifactorial: SERDs are more effective and better tolerated than AIs. Critically, they also prevent the most common resistance mechanism—the acquisition of ESR1 mutations—from developing in the first place, altering the disease's future trajectory.

ESR1 mutations are rarely found in primary tumors but develop in metastatic settings under pressure from aromatase inhibitors, conferring resistance. This evolution necessitates serial, plasma-based genotyping upon each disease progression to identify these actionable mutations as they emerge.

A study switching therapy based on ctDNA-detected ESR1 mutations revealed patients felt significantly better after the switch, even without visible tumor progression on scans. This counterintuitive finding suggests molecular progression has a subclinical impact on quality of life, supporting proactive, biomarker-driven treatment changes before patients clinically deteriorate.

The SERINA-6 trial suggests a paradigm shift: proactively switching from an AI to an oral SERD upon detecting an ESR1 mutation in ctDNA—before clinical or radiographic progression—significantly improves progression-free survival and patient quality of life.

SERENNA-six pioneers a strategy where treatment is switched upon detecting an ESR1 resistance mutation in ctDNA, *before* the patient shows clinical signs of progression. This proactive, biomarker-driven approach represents a paradigm shift from reactive treatment of progressing disease.

Despite the promise of liquid biopsies for monitoring, the SERENA-6 trial revealed a significant challenge: fewer than 10% of screened patients developed a detectable ESR1 mutation. This low yield questions the efficiency and broad applicability of this serial screening strategy to guide treatment changes.

Circulating tumor DNA (ctDNA) analysis allows for early detection of resistance mechanisms, such as secondary FGFR2 mutations, before tumors show growth on scans. This provides a potential window to adjust treatment strategies proactively, offering an advantage over traditional imaging-based monitoring.

The SERINA-6 trial supports a paradigm shift: proactively screening for ESR1 mutations via blood test and switching to camisestrant upon detection, even without radiological progression. This early switch based on molecular signals nearly doubled median progression-free survival from 9 to 16 months.